Core Viewpoint - Fosun Pharma's subsidiary has received approval from the National Medical Products Administration of China for the listing of "Mizartin Potassium Tablets," which are indicated for the treatment of primary hypertension [1][2] Group 1: Product Details - "Mizartin Potassium Tablets" contain the active ingredient Mizartin Potassium, which acts as an angiotensin II receptor antagonist, effectively lowering blood pressure by blocking the angiotensin II hormone [1] - The product is classified as a Class B drug by the National Medical Insurance Administration, with no restrictions on insurance indications or disease types, making it a first-line antihypertensive medication for adults with primary hypertension [1] - The product is available in two dosages, 40mg and 80mg, catering to patients with mild to moderate and severe hypertension, respectively [2] Group 2: Market Context - The "sartan" class of antihypertensive drugs holds over 80% market share in the overall renin-angiotensin system (RAS) market, with sales exceeding 10 billion RMB in 2022, highlighting the significant role of "sartan" drugs in the hypertension medication family [1] - The development of "Mizartin Potassium Tablets" aligns with the company's strategy to enhance its product pipeline in the cardiovascular system sector [2]
福森药业：“美阿沙坦钾片”获批上市